KRAS G12C Mutation in Lung Cancer: From 'Undruggable' to Targetable
KRAS is one of the most commonly mutated genes in lung cancer, and for decades it was considered undruggable until researchers developed inhibitors specifically targeting the KRAS G12C mutation subtype.
KRAS is a gene involved in a cell-signaling pathway that controls growth. Mutations in KRAS are common across several cancer types, but for many years the protein's structure made it extremely difficult to design a drug that could bind to and block it โ earning it a reputation as 'undruggable' in cancer research circles.
That changed with the discovery of a specific pocket on the mutated KRAS G12C protein that could be targeted by small-molecule inhibitors, leading to the first FDA-approved KRAS G12C-specific drugs earlier this decade. This breakthrough opened an entirely new research track focused on other KRAS mutation subtypes beyond G12C.
Current research is now exploring combining KRAS G12C inhibitors with immunotherapy, aiming for chemotherapy-free treatment approaches in newly diagnosed patients with this specific mutation.
Frequently Asked Questions
Is KRAS G12C the only targetable KRAS mutation?
It's the first and most extensively studied, but research into other KRAS mutation subtypes is ongoing.
Why was KRAS considered undruggable for so long?
The protein's smooth surface structure lacked an obvious binding pocket for small-molecule drugs until researchers identified a specific pocket unique to the G12C mutant form.